Yonsei Med J.  2021 Sep;62(9):829-835. 10.3349/ymj.2021.62.9.829.

Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study

Affiliations
  • 1Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
  • 2Center for Frontier Medical Engineering, Chiba University, Chiba, Japan
  • 3Department of Orthopaedic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
  • 4Department of Orthopaedic Surgery, Eastern Chiba Medical Center, Togane, Japan
  • 5Department of Orthopaedic Surgery, Seirei Sakura Citizen Hospital, Sakura, Japan
  • 6Department of Orthopaedic Surgery, St. Marianna University School of Medicine, Kawasaki, Japan
  • 7Department of Orthopaedic Surgery, Toho University Sakura Medical Center, Sakura, Japan
  • 8Department of Orthopaedic Surgery, Chiba Cancer Center, Chiba, Japan

Abstract

Purpose
In this multicenter retrospective observational study, we examined the early effects of romosozumab in patients with severe osteoporosis in terms of time-course changes in bone metabolism marker, improvement in bone density, and adverse effects.
Materials and Methods
Patients with severe osteoporosis were included. We investigated the progress of TRACP 5b and P1NP before and 1–2 months after the administration of romosozumab. We also investigated the bone density of lumbar spine, femoral neck, and the entire femur, measured by the DXA method, before and 5–7 months after the administration of romosozumab.
Results
A total of 70 patients (7 males and 63 females, age 75.0±3.6 years) participated in this study. Significant improvements in TRACP 5b and P1NP levels were observed before and 1–2 months after romosozumab administration. The average bone density of lumbar spine, femoral neck, and the entire femur were measured before and 5–7 months after romosozumab administration; and a significant increase only observed in the lumbar spine.
Conclusion
Consistent with the findings of previous clinical studies, romosozumab has both bone formation-enhancing and bone resorption effects (dual effect). In addition, romosozumab also demonstrated improvement in bone density from the early phase after the administration, though the result was only seen in the lumbar spine.

Keyword

Bone and bones; bone density; bone resorption; metabolism; osteogenesis; osteoporosis
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr